| pubmed-article:8580802 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8580802 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
| pubmed-article:8580802 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:8580802 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
| pubmed-article:8580802 | lifeskim:mentions | umls-concept:C1333784 | lld:lifeskim |
| pubmed-article:8580802 | lifeskim:mentions | umls-concept:C0205103 | lld:lifeskim |
| pubmed-article:8580802 | lifeskim:mentions | umls-concept:C0033522 | lld:lifeskim |
| pubmed-article:8580802 | lifeskim:mentions | umls-concept:C1518388 | lld:lifeskim |
| pubmed-article:8580802 | lifeskim:mentions | umls-concept:C0205225 | lld:lifeskim |
| pubmed-article:8580802 | pubmed:issue | 3-4 | lld:pubmed |
| pubmed-article:8580802 | pubmed:dateCreated | 1996-3-19 | lld:pubmed |
| pubmed-article:8580802 | pubmed:abstractText | The role of surgery as initial treatment in gastric lymphoma remains controversial. We have prospectively evaluated a stomach conservation strategy in histologically aggressive gastric lymphoma, using primary adriamycin-containing chemotherapy, followed by involved-field radiotherapy in patients with limited disease. Twenty-six patients (median age 69 years) were entered in this study; 15 had stage I disease, 7 had stage II disease and 4 had stage IV disease. The chemotherapy combinations were CHOP (18 patients) and ProMACE/MOPP (8 patients). Radiotherapy was given to 11 patients. Of the 24 patients evaluated for response, 18 (75%) achieved endoscopically-confirmed complete response and 4 (17%) partial response. During follow-up (median 22 months), none of the complete responders developed recurrent lymphoma. Gastric resection was performed in 1/26 patients who did not respond to primary chemotherapy. There were no cases of perforation, but three patients (12%) developed acute gastro-intestinal bleeding a few days after the onset of chemotherapy, one of whom required a surgical devascularization procedure. There was no treatment-related mortality. These data further support the non-surgical approach in histologically aggressive gastric lymphoma, using primary chemotherapy with or without radiation therapy. | lld:pubmed |
| pubmed-article:8580802 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8580802 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8580802 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8580802 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8580802 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:8580802 | pubmed:issn | 1042-8194 | lld:pubmed |
| pubmed-article:8580802 | pubmed:author | pubmed-author:FreidinNN | lld:pubmed |
| pubmed-article:8580802 | pubmed:author | pubmed-author:HaimNN | lld:pubmed |
| pubmed-article:8580802 | pubmed:author | pubmed-author:ReshefRR | lld:pubmed |
| pubmed-article:8580802 | pubmed:author | pubmed-author:Ben-AriehYY | lld:pubmed |
| pubmed-article:8580802 | pubmed:author | pubmed-author:Ben-ShaharMM | lld:pubmed |
| pubmed-article:8580802 | pubmed:author | pubmed-author:EpelbaumRR | lld:pubmed |
| pubmed-article:8580802 | pubmed:author | pubmed-author:LeviovMM | lld:pubmed |
| pubmed-article:8580802 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8580802 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:8580802 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8580802 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8580802 | pubmed:pagination | 321-6 | lld:pubmed |
| pubmed-article:8580802 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:meshHeading | pubmed-meshheading:8580802-... | lld:pubmed |
| pubmed-article:8580802 | pubmed:year | 1995 | lld:pubmed |
| pubmed-article:8580802 | pubmed:articleTitle | Intermediate and high-grade gastric non-Hodgkin's lymphoma: a prospective study of non-surgical treatment with primary chemotherapy, with or without radiotherapy. | lld:pubmed |
| pubmed-article:8580802 | pubmed:affiliation | Department of Oncology, Rambam Medical Center, Haifa, Israel. | lld:pubmed |
| pubmed-article:8580802 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8580802 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8580802 | pubmed:publicationType | Controlled Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8580802 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8580802 | lld:pubmed |
